Abstract
Non-VKA oral anticoagulants (NOACs), thanks to their ease of use and their similar or superior safety/efficacy profiles versus warfarin, have now widely reached the lucrative market of anticoagulation. However, while the marketing authorization holders always claim, in a quite unclear way that no monitoring is required, accumulative evidence and cases of major bleeding have been described in the literature and reported by spontaneous reporting systems at the regulator's level. These compounds are usually given at fixed doses without routine coagulation monitoring. However, new data suggests that an assessment of the response at the individual level could improve the benefit-risk ratio of, at least dabigatran. Therefore, in certain patient populations, i.e. acute or chronic renal impairment or multiple drug interactions, measurement of drug exposure may be useful to ensure an optimal treatment response. More specific circumstances such as patients experiencing a haemorrhagic or thromboembolic event during the treatment duration, patients who require urgent surgery or an invasive procedure, or patient with a suspected overdose could benefit from such a measurement. This article aims at providing guidance on how to best estimate the intensity of anticoagulation using laboratory assays in daily practice.
Translated title of the contribution | Non-VKA oral anticoagulants: An update for the clinical biologists |
---|---|
Original language | French |
Pages (from-to) | 333-344 |
Number of pages | 12 |
Journal | Annales de biologie clinique |
Volume | 73 |
Issue number | 3 |
DOIs | |
Publication status | Published - 1 May 2015 |
Keywords
- Anticoagulant
- Apixaban
- Coagulation
- Dabigatran
- Monitoring
- NOAC
- Rivaroxaban
Fingerprint
Dive into the research topics of 'Non-VKA oral anticoagulants: An update for the clinical biologists'. Together they form a unique fingerprint.Student theses
-
Evaluation of thrombotic and/or bleeding risks associated with anticoagulotherapy.
Douxfils, J. (Author), Dogne, J.-M. (Supervisor), Mullier, F. (Supervisor), Masereel, B. (President), Chatelain, B. (Jury), Chatelain, C. (Jury), Verhamme, P. (Jury), TEN CATE, H. (Jury) & Ageno, W. (Jury), 24 Oct 2015Student thesis: Doc types › Doctor of Biomedical and Pharmaceutical Sciences